In this meta-analysis, we aimed to assess the evidence from neuroimaging studies for chronic alterations in the brains of MDMA users. The databases PubMed, Embase, and Web of Science were searched for studies published from inception to August 24, 2018, without any language restriction. Sixteen independent studies comprising 356 MDMA users and 311 controls were included. Of these, five studies investigated frontal and occipital Nacetylaspartate/creatine and myo-inositol/creatine ratios, three studies assessed basal ganglia blood flow and ten studies investigated serotonin transporter (SERT) density in various regions. We found significantly decreased SERT density in eight of 13 investigated regions.
A C C E P T E D M A N U S C R I P T
Introduction
A C C E P T E D M A N U S C R I P T MDMA (3,4-methylenedioxymethamphetamine) is an amphetamine that primarily acts as a serotonin and norepinephrine releasing agent (Hysek et al., 2012) . MDMA is the most common psychoactive component found in drugs sold as "ecstasy" (Morefield et al., 2011) and one of the most commonly used illicit drugs (UNODC, 2017) . Prior to its rise as a recreational drug in the 1980s, MDMA was used by several psychotherapists as an adjunct in psychotherapy. This approach was readopted a few years ago, and research has continued on the use of MDMA in the therapy of posttraumatic stress disorder (Mithoefer et al., 2018; Mithoefer et al., 2013; Oehen et al., 2013) . However, there are concerns that MDMA might be neurotoxic in humans, especially to serotonergic neurones (Carvalho et al., 2012) . In the last 30 years, numerous studies investigating this issue have been published. However, studies mostly focused on heavy users (Szigeti et al., 2018) , their results were heterogeneous and the debate is still continuing. Despite the large volume of data, few attempts have been made to meta-analytically summarise previous findings. To our knowledge, only one meta-analysis on neuroimaging in MDMA users has been published (Roberts et al., 2016) . The authors aggregated findings on serotonin transporter (SERT) and serotonin 2A receptor density in current MDMA users and concluded that MDMA use was associated with reduced SERT availability in 11 of 14 investigated brain regions. The present meta-analysis extends this investigation to all neuroimaging modalities and current as well as previous users, and aims to provide a complete meta-analytical account of the literature on neuroimaging in human MDMA use. Furthermore, we examine possible relationships between alterations in SERT density and lifetime episodes of MDMA consumption using meta-regression. We also include time of abstinence from MDMA as an explanatory variable in this model, as several studies have indicated that reductions in SERT density might be reversible to some extent (Buchert et al., 2006; McCann et al., 2005; Reneman et al., 2001a; Selvaraj et al., 2009; Semple et al., 1999; Thomasius et al., 2003) .
A C C E P T E D M
A N U S C R I P T
Methods
To ensure quality of reporting throughout the entire process, we adhered to the recommendation for systematic reviews and meta-analysis in the PRISMA statement (Moher et al., 2015) and the MOOSE guidelines for meta-analyses and systematic reviews of observational studies (Stroup et al., 2000) .
Search strategy
The data bases PubMed, Embase, and Web of Science Core Collection were searched to identify studies from inception to August 24, 2018, without any language restriction. The following search term was used: (mdma OR ecstasy OR 3,4-methylenedioxymethamphetamine) AND (mri OR smri OR fmri OR pwi OR dti OR mrs OR pet OR spect OR imaging OR neuroimaging OR "magnetic resonance imaging" OR "perfusion weighted imaging" OR "diffusion tensor imaging" OR "magnetic resonance spectroscopy" OR "positron emission tomography" OR "single photon emission computed tomography"). Once a study had been rated as eligible from a full text review, its reference list was manually screened for other relevant studies.
Search strategy and selection criteria
The whole process of study selection and data extraction was conducted by two investigators (FM, RB) independently. In case of disagreement, the reviewers discussed their reasons. If consensus was not reached, a third investigator (SB) was included.
Firstly, duplicates were removed. Titles and abstracts of all remaining records were reviewed and publications which did not meet inclusion criteria were excluded. The remaining publications were screened on the basis of a review of the full text. Inclusion criteria were 1) investigation of non-acute effects of MDMA on the human brain, 2) comparison of an
MDMA user group with a control group, 3) application of structural, functional or neurochemical neuroimaging techniques (namely magnetic resonance imaging (MRI) -including functional MRI (fMRI), structural MRI (sMRI), diffusion tensor imaging (DWI), perfusion weighted imaging (PWI) and proton magnetic resonance spectroscopy (1H-MRS) -, positron emission tomography (PET) and single photon emission computed tomography (SPECT)), and 4) sufficient data for meta-analysis -either reported or received from the authors on request.
Studies which met inclusion criteria were classified into those applying whole brain approaches and those applying region of interest (ROI) approaches. Studies were further classified into domains (investigations of SERT density, dopamine transporter density, serotonin 2A receptor density, glucose metabolism, neurochemical markers, structural measures, resting state conditions, task-based conditions, etc.). If necessary, these categories were further divided into subcategories, in order to allow direct comparisons (e.g. investigations of neurochemicals were divided into the respective markers).
In cases of overlapping samples, the study with the largest sample size was included. If overlaps between studies were suspected but the original publications did not contain information on that topic, authors were contacted to request this information. If studies reported longitudinal data, the last time point was used.
If the same study reported data on overlapping ROIs, the larger region was included and the smaller region was discarded (e.g. an ROI of the frontal cortex was preferred to an ROI of the orbitofrontal cortex). If a specified ROI was investigated for the same modality in at least three independent data sets, meta-analysis was conducted for this specific modality. We initially planned to aggregate studies reporting results on a whole brain level using Seedbased d mapping (Radua and Mataix-Cols, 2012) if at least five studies were available for a given modality. Furthermore, we intended to aggregate associations (reported as Pearson`s correlation coefficients) between cumulative lifetime doses and time of abstinence and
neuroimaging measures -if at least three studies were available. However, neither of these analyses was conducted, as there were not enough studies available. Details on excluded studies are reported in supplementary results.The methods reported below therefore only apply to meta-analytical procedures for ROI studies.
Recorded variables and data extraction
Recorded variables comprised general information (centre where the study was performed, authors, year of publication, study design, imaging method, number of subjects, recruitment strategies, and incentives for participation) and several demographic variables (age, gender, cumulative lifetime exposure to ecstasy (tablets, episodes, dosage in mg), usual MDMA dose per occasion, maximum MDMA dose per occasion, age at onset of MDMA use, time since last MDMA use, duration of MDMA use, and reported matching of control group for use of other drugs). When data on drug history were missing but could be computed from the original publication, the missing values were calculated. If necessary, units were transformed.
To calculate effect sizes, means and standard deviations (SD) of the respective neuroimaging outcome were extracted for MDMA users and controls. Where these data were not published and were not received on request, effect sizes were estimated in the following order: estimation of mean and SD from published figures (using the software PlotDigitizer; http://plotdigitizer.sourceforge.net) > estimation based on t values > estimation based on z values > estimation based on p value. If studies reported data on drug-naïve and polydrug controls, the latter groups were preferred. In cases where more than one MDMA user group was reported, values were treated as independent data sets and the number of control subjects was adjusted by dividing them by the number of user groups. If standard errors of the mean (SE) were reported, values were converted using the formula = √ × . If ROIs were separately reported for the right and left hemispheres, values (mean and SD) were averaged. (Brunt et al., 2012; Cole et al., 2002; Jalali et al., 2016; Khajeamiri et al., 2011; Mc Fadden et al., 2006; Schneider and Kovar, 2003; Sherlock et al., 1999; Shetab Boushehri et al., 2009; Togni et al., 2015) . Compared with lifetime intake of tablets, we expected less variation in terms of "episodes of use" (i.e. we assume that episodes of use approximately amount to similar quantities of MDMA across different countries and periods). "Episodes of MDMA use" were not reported by eight included studies (Buchert et al., 2007; Cowan et al., 2007; Daumann et al., 2004; de Win et al., 2008; Kish et al., 2010; Reneman et al., 2002b; Reneman et al., 2001b; Semple et al., 1999) . These missing values were calculated by dividing "cumulative lifetime use in tablets" by "usual dose per episode" reported in the respective studies. In cases where "usual dose per episode" was not available, a weighted mean of tablets per episode was calculated across all included studies, resulting in a value of 3.0 tablets/episode. This value was higher than a similar estimate (1.3 tablets/episode) recently reported by our group (Mueller et al., 2015) ; however, our previous work focused on moderate MDMA use and a higher value can be expected in other samples.
Statistical analysis
Meta-analysis of region of interests was performed using the R package metafor (version 2.0-0; www.metafor-project.org) and OpenMEE (www.cebm.brown.edu/openmee) (Wallace et al., 2009) . Because most studies investigated small samples (mean number of subjects in user
groups: 21, mean number of subjects in control groups: 22), effect sizes were calculated using Hedges' g, which offers a correction for small sample sizes. A random effects model (restricted maximum likelihood estimation) was used to calculate the pooled effect size, as high heterogeneity was suspected (e.g. due to different drug use patterns) and there was no reason to suspect that the true effect size was the same across studies. Heterogeneity was assessed using the I 2 value. Additionally, a leave-one-out meta-analysis was conducted. This was done to assess the robustness of the results by iteratively removing one study at a time.
Moderator analysis
Potential influences of the variables "lifetime episodes of MDMA use" and "time of abstinence from MDMA" on neuroimaging measures were assessed using meta-regression.
This analysis was performed if at least ten assessments were available for a given domain (Higgins and Green, 2008) . This criterion was met for studies investigating SERT density. We also initially planned to investigate potential influences of the variables "usual dose per episode" and "maximum dose per episode", but the included studies did not provide enough data ("usual dose per episode" was reported for eight assessments and "maximum dose per episode" was reported for five assessments only). In order to account for dependent measurements, multiple outcomes (i.e. results for different ROIs) within the same study were summarised by calculating combined effect sizes and variances, using procedures described by Borenstein (Borenstein, 2009) . This calculation requires an estimate of the correlation between brain regions in neuroimaging measures, as assessed on the basis of previously reported data (see supplement for more details) (Erritzoe et al., 2010) . The resulting effect sizes and variances (one for each study) were entered as dependent variables in the metaregression model. "Lifetime episodes of MDMA use" and "time of abstinence from MDMA"
were entered as explanatory variables. Meta-regression was calculated using a random effects
model (restricted maximum likelihood estimation). Statistical significance was assumed at p<0.05.
Assessment of publication bias
As the number of studies was small for all investigated domains, assessment of publication bias using funnel plots might be inappropriate (Higgins and Green, 2008) . Publication bias was therefore assessed using Rosenberg's fail-safe N approach (Rosenberg, 2005) . The failsafe N indicates the number of unpublished non-significant (effect size of zero) studies that would be required to equalise the statistically significant effect of the studies included in the meta-analysis. Fail-safe N was calculated for each significant outcome; the target significance level was p<0.05.
Quality assessment of included studies
The quality of all included studies was assessed with the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies of the National Heart, Lung, and Blood
Institute of the United States National Institutes of Health (NIH). Mean values and SD of neuroimaging outcomes were received upon request for one study (Selvaraj et al., 2009 ) and values were estimated from figures for two studies (Erritzoe et al., 2011; McCann et al., 1998) . A flow diagram of the selection procedure is given in figure 1 .
Results
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Most of the studies assessed on the basis of the full text review reported heterogeneous assessments which were not suitable for meta-analysis as based on our criteria described above (see supplementary results). Three studies reported additional results obtained with diverse methodologies. This required post hoc decisions on the inclusion and exclusion of different approaches. Reasons for decisions are given in the supplementary results.
Proton magnetic resonance spectroscopy
Data of five 1 H-MRS studies (Chang et al., 1999; Cowan et al., 2007; Daumann et al., 2004; de Win et al., 2008; Reneman et al., 2002b) were included in the analysis of NAA/CR ratios in the occipital lobe (110 users, 120 controls). Across all studies, participants had a mean of 
Cerebral blood flow
Data from CBF studies in two regions of interest -globus pallidus and putamen -were investigated by two MRI studies (de Win et al., 2008; Reneman et al., 2001b) and one SPECT study (Chang et al., 2000) (83 users and 81 controls) and showed no evidence for a significant difference in CBF between MDMA users and controls in these regions (globus pallidus:
g=0.14, CI95%= [-0.80 
Serotonin transporter density
We included ten studies which investigated SERT density using PET (Buchert et al., 2007; Erritzoe et al., 2011; Kish et al., 2010; McCann et al., 1998; McCann et al., 2005; McCann et al., 2008; Selvaraj et al., 2009; Urban et al., 2012) and SPECT (de Win et al., 2008; Semple et al., 1999) in a total of 267 users and 234 controls. Across studies, participants had a mean of 169.1 lifetime episodes of ecstasy use (range: 2.0 -243.8 episodes). All studies contributed more than one region to the meta-analysis. One study (Erritzoe et al., 2011) reported a clear outlier for the amygdala (see supplementary figure 1), which was removed from further analysis. However, exclusion of this study did not significantly alter the results (see supplementary figure 1). (Frankle et al., 2004; Frankle et al., 2006; Szabo et al., 1995) . Two other studies (de Win et al., 2008; Semple et al., 1999) used the radiotracer [ 123 I]ß-CIT, which is not specific to SERT but also binds to the dopamine transporter (Abi-Dargham et al., 1996; Laruelle et al., 1993) . Use of this tracer in dopamine transporter-rich regions (especially caudate and putamen) might therefore be misleading. One study used [ 123 I]ß-CIT for the investigation of caudate and putamen (Semple et al., 1999) . However, removal of this study did not alter the results (see supplementary figure 2 ). Overall, leave-one-out meta-analysis did not substantially alter results for most regions in terms of significance (see supplementary table 3 ). However, removal of some studies resulted in non-significant results for amygdala (McCann et al., 2005; McCann et al., 2008) , anterior cingulate (Kish et al., 2010) , and hippocampus (Kish et al., 2010; McCann et al., 2005; McCann et al., 2008) . and Green, 2008) . However, these findings should be interpreted with caution, as I 2 can be biased when the number of investigated studies is small (von Hippel, 2015) .
Moderator analysis
Meta-regression indicated no association between the explanatory variable "lifetime episodes of MDMA use" and aggregated effect sizes for SERT density (ß=0.001, Z=0.27, p=0.79). In contrast, a positive association was found between SERT density and time of abstinence (ß=0.001, Z=2.11, p=0.04). See figure 5 for plots of both meta-regressions. However, most of the studies reported relatively similar times of abstinence and the association for this variable seemed to be largely driven by a single study (Selvaraj et al., 2009 ). Indeed, removal of this study considerably altered the result (ß=0.000, Z=0.44, p=0.66), which questions the validity of this analysis.
Publication bias
Rosenberg`s fail-safe N indicated that high numbers of unpublished non-significant studies (effect sizes of zero) would be needed to bring the p value of the effect to >0.05 for most of the regions where significant alterations in SERT density were found (parietal lobe: 68, temporal lobe: 72, occipital lobe: 125, anterior cingulate: 28, posterior cingulate: 114, hippocampus: 41). Fail-safe N was significantly lower for amygdala (12 studies) and
thalamus (13 studies). Although there is no strict criterion, the number of studies seem to be sufficiently high in all cases, maybe with the exception of amygdala and thalamus, thus making it unlikely that the reported results are exclusively due to publication bias.
Quality assessment of included studies
The included studies exhibited various sources of bias and were of poor quality. Common problems were recruitment of user and control groups from different populations ("rave scene" versus general population), which could introduce various differences and potential confounding by, for example, use of other illicit drugs. It is striking that, in all but one study, there were significant differences between control and user groups in the use of drugs other than MDMA (please see table 1 for more details). Other problems were related to issues which are inherent to these designs, such as unreliable measures of exposure to MDMA.
Details of the assessment are shown in the supplementary results.
Discussion
This work provides a comprehensive meta-analytical account of the current evidence from neuroimaging studies in MDMA users. The studies mostly comprised heavy users with concomitant use of various other drugs. Compared with controls, these samples exhibit reduced SERT densities, while no alterations were observed in neurochemical markers and CBF.
In more detail, SERT density was found to be significantly lower in MDMA users in eight out of 13 investigated regions (namely: parietal, temporal and occipital lobe, anterior and posterior cingulate, thalamus, and hippocampus). In contrast, we found no evidence for an association between MDMA use and alterations in terms of CBF in the basal ganglia and of NAA/CR and MI/CR ratios in the mid-frontal and occipital lobes. Especially in the case of
CBF, these analyses were limited to a specific region, although the basal ganglia exhibit dense serotonergic innervations (Liu et al., 2011; Miguelez et al., 2014) (Biezonski and Meyer, 2010; Kivell et al., 2010) . Surprisingly, meta-regression indicated no relationship between lifetime episodes of MDMA use and reductions in SERT density. It has been suspected that neurotoxic effects of MDMA rather depend on doses taken per occasion than on cumulative lifetime intake (Fox et al., 2001) , which could explain the absence of a cumulative dose-response relationship. It would have been interesting to additionally investigate associations with usual and maximal doses per occasion. However, this information has only been reported in a few studies, which renders further investigation impossible. In contrast, a significant association was found between time of abstinence and SERT density. This finding might suggest that reductions in SERT are potentially reversible, as already suspected by several authors (Buchert et al., 2006; McCann et al., 2005; Reneman et al., 2001a; Selvaraj et al., 2009; Semple et al., 1999; Thomasius et al., 2003) . However, exclusion of one study had a relative large impact on the result of the meta-regression, so this finding comes with some uncertainty. Moreover, there is some evidence for regional differences in recovery from SERT loss (Erritzoe et al., 2011; Hatzidimitriou et al., 1999; Scheffel et al., 1998) , a possibility which could not be assessed in our analysis. Additionally, if these findings were to represent recovery of SERT, it is unclear whether the system is restored to integrity or to some abnormal state, as indicated by findings in animals (Fischer et al., 1995) , as neuroimaging measures only provide information on a macro systems level.
We have already pointed out elsewhere (Mueller et al., 2015) that moderate MDMA use might be a neglected field of research as there is evidence that heavy users are only a minority among MDMA users (von Sydow et al., 2002) . It has been recently estimated that MDMA users in neuroimaging studies consume approximately seven times more MDMA per year than the average user and that these subjects correspond to the top 5-10% of the Global Drug Survey sample (Szigeti et al., 2018) . Therefore, neuroimaging studies might overestimate effects. This is also reflected in the present work. According to a common, but non-empirical, definition for moderate use (<50 lifetime episodes or <100 lifetime tablets), all but one study in this meta-analysis investigated heavy users and thus might not be representative. This particularly applies to the significance of these studies for investigations on the therapeutic use of MDMA in posttraumatic stress disorder, where only a few single doses of MDMA of typically 125 mg are administered in a calm setting (Mithoefer et al., 2018; Mithoefer et al., 2011; Oehen et al., 2013) . This approach mostly involves low cumulative doses of MDMA, e.g. a dose of 375 mg was used in the pilot study by Mithoefer et al. (Mithoefer et al., 2011) and doses between 375 and 525 mg per subject were administered in a consecutive study (Mithoefer et al., 2018) . Only one (de Win et al., 2008) of the studies included in this metaanalysis investigated a comparable low cumulative dose. In this study, user reported an average lifetime dose of six tablets which (given data on MDMA content of ecstasy tablets in the Netherlands during this period) roughly corresponds to doses used by Mithoefer et al. (Brunt et al., 2012) . No significant alterations in terms of CBF, MRS, and SERT density were found in this study.
This meta-analysis has several strengths. Firstly, we provide a complete meta-analytical account of the current literature. We included current as well as former users, because we were also interested in potential recovery of altered neuroimaging measures. Compared with a previous meta-analysis (Roberts et al., 2016) , this resulted in a larger set of studies and this also allowed assessment of potential moderators using meta-regression. Moreover, we
standardised lifetime MDMA doses across studies; this increases comparability and is also a prerequisite for meta-regression. On the other hand, our analysis is limited by several factors, including studies with small sample sizes, observational designs, and various possible confounders between users and controls, including possible pre-existing psychological or biological differences, use of an unknown amount of MDMA, contamination with other used substances, and life-style related factors. It is striking that only one of the included studies (Selvaraj et al., 2009 ) provided a control group which reportedly exhibited no significant differences in use of other drugs than MDMA. Confounding effects by other drugs than MDMA might be one of the main problems in this field. The included studies exhibit various heterogeneities which complicate comparisons, e.g. times of abstinence from MDMA vary widely across studies. Leave-one-out meta-analysis revealed that some results on SERT density were not robust, which also indicates substantial heterogeneity between studies. Our standardisation of lifetime episodes of MDMA use is only an estimate of the lifetime use of MDMA, as ecstasy use per episode might vary between countries and over time. Additionally, data on episodes of use is likely to be imprecise, as subjects probably had difficulties in remembering all occasions. These uncertainties might have influenced the results of the metaregression model. Overall, the quality of the included studies was poor. It is evident that shortcomings in primary studies will be carried over to the meta-analysis and thus weaken its conclusions. However, the quality assessment tool used was not specifically designed for neuroimaging studies and might comprise criteria which are difficult to meet in research on MDMA. Most of the included studies explicitly aimed to evaluate (serotonergic) neurotoxicity in MDMA users. For example, cerebral blood flow is thought to be associated with the vasoactive properties of serotonin (Chang et al., 2000; de Win et al., 2008; Reneman et al., 2001b) . In the case of MRS, NAA is considered to be a marker for neurones and MI an indicator for glial cells, while CR serves as a reference with concentrations assumed to be stable. The included MRS studies explicitly aimed to evaluate neurotoxic effects of MDMA Daumann et al., 2004; de Win et al., 2008; Reneman et al., 2002b) . However, the two techniques do not specifically assess serotonergic neurotoxicity and to our knowledge have not been validated for this purpose.
Conclusion
Although MDMA use has been examined by means of neuroimaging for over 20 years, approaches are very heterogeneous and replications are rather scarce. Therefore, our analysis is limited by the small number of studies and restricted to a few regions, especially in the case of CBF. We found no evidence for alterations in CBF in the basal ganglia and in neurochemical markers in the occipital and frontal lobes. SERT density was found to be decreased in several regions. Surprisingly, meta-regression indicated no association between these alterations and lifetime episodes of MDMA use. Consequently, other factors -such as doses taken per occasion -might be more important determinants. It is also possible that reductions in SERT density are related to factors other than MDMA. For the future, it would be desirable to see studies of better quality and more attempts to replicate previous findings in this area. Particular attention should be paid to potential confounding by other drugs than MDMA, by e.g., recruitment of controls from the same population as user groups and more rigorous attempts to statistically control for these factors. Previous investigations have largely focused on heavy use patterns and it would be preferable to see more studies in low to moderate users and in people who have previously used MDMA but are currently not using it.
Further attempts to determine the causes of reduced SERT density (e.g. neurotoxic effects or transporter down regulation) would be advantageous. 
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We would like to thank three anonymous reviewers for their helpful and constructive comments. proportional to the weight in the meta-regression. There was no significant association between lifetime episodes of MDMA use and reduction in SERT density. In contrast, time of abstinence was positively associated with SERT density (p<0.05). However, exclusion of one study had a relative large impact on the result of the metaregression, so this finding is somewhat uncertain. 
